Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Oisin Biotechnologies is raising $5,000,000.00 in new funding. Sources indicate as part of senior management President, Matthew Scholz played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Oisin Biotechnologies

Oisin Biotechnologies is a platform drug development company focused on creating drugs to combat a variety of age related diseases. SENSOlytics is an Oisin proprietary platform technology that enables precise targeting of a senescent cell based on the DNA expression of the cell, not on surface markers or other characteristics that might be shared with normal, undamaged cells.

To learn more about Oisin Biotechnologies, visit http://www.oisinbio.com/

Contact:
Matthew Scholz, President
206-880-1166
https://www.linkedin.com/in/matthewscholz/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved